SCHEDULE 13G/A: Millennium Entities Reduce Stake in Adaptive Biotechnologies, Beneficial Ownership Falls Below 5%

Millennium Management LLC and affiliated entities have filed an amended Schedule 13G, indicating a reduction in their beneficial ownership of Adaptive Biotechnologies Corporation's common stock, with individual holdings now below 5% as of December 31, 2024.

Summary

• Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have filed an Amendment No. 2 to Schedule 13G regarding their beneficial ownership of Adaptive Biotechnologies Corporation's common stock.
• As of December 31, 2024, Integrated Core Strategies (US) LLC beneficially owned 5,622,214 shares, representing 3.8% of the class.
• Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander each beneficially owned 6,292,634 shares, representing 4.3% of the class.
• All reported shares are held with shared voting and shared dispositive power by the respective reporting persons.
• The filing indicates that the aggregate amount beneficially owned by each reporting person is 5% or less of the class, suggesting a reduction in their stake from previous filings.
• The entities are filing as a group, as confirmed by the Joint Filing Agreement dated January 24, 2025.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the reduction in beneficial ownership by a major institutional investor group, which can be perceived as a lack of confidence in the company's future prospects.

Negatives

• The filing indicates a reduction in beneficial ownership by Millennium Management LLC and its affiliated entities, with individual holdings now falling below the 5% threshold, which could be interpreted as a decrease in confidence by a significant institutional investor.

Future Outlook

NA

Industry Context

This filing reflects a change in a significant institutional investor's position in Adaptive Biotechnologies, a company operating in the biotechnology sector. Such changes can sometimes signal shifts in investor sentiment towards the company or the broader industry, though this specific filing does not provide reasons for the change.

Stakeholder Impact

• Shareholders may view the reduction in stake by a prominent institutional investor as a negative signal, potentially impacting stock price due to perceived decreased institutional confidence.

Key Dates

Recommendation

Keywords

Adaptive Biotechnologies Corporation, Millennium Management LLC, Integrated Core Strategies (US) LLC, Israel A. Englander, Schedule 13G/A, Beneficial Ownership, Institutional Investment, Equity Stake, SEC Filing